SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Karpouzas George A.)
 

Sökning: WFRF:(Karpouzas George A.) > Biological use infl...

  • Karpouzas, George AthanasiosInternal Medicine - Rheumatology, CA, Torrance, United States; Harbor-UCLA Medical Center, Rheumatology, CA, Torrance, United States (författare)

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • BMJ Publishing Group Ltd,2024
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-228118
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-228118URI
  • https://doi.org/10.1136/rmdopen-2024-004546DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Objectives: Chronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA.Methods: We studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death; and (2) any ischaemic cardiovascular events (iCVE) including MACE plus revascularisation, angina, transient ischaemic attack and peripheral arterial disease.Results: Over 26 534 patient-years, 239 MACE and 362 iCVE occurred. The interaction between 28-joint Disease Activity Score with C-reactive protein (DAS28-CRP) and bDMARD use was significant for MACE (p=0.017), suggesting the effect of DAS28-CRP on MACE risk differed among bDMARD users (n=515) and non-users (n=3855). DAS28-CRP (per unit increase) is associated with MACE risk in bDMARD non-users (HR 1.21 (95% CI 1.07 to 1.37)) but not users (HR 0.69 (95% CI 0.40 to 1.20)). The interaction between CRP (per log unit increase) and bDMARD use was also significant for MACE (p=0.011). CRP associated with MACE risk in bDMARD non-users (HR 1.16 (95% CI 1.04 to 1.30)), but not users (HR 0.65 (95% CI 0.36 to 1.17)). No interaction was observed between bDMARD use and DAS28-CRP (p=0.167) or CRP (p=0.237) for iCVE risk.Conclusions: RA activity and inflammatory markers associated with risk of MACE in bDMARD non-users but not users suggesting the possibility of biological-specific benefits locally on arterial wall independently of effects on systemic inflammation.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Ormseth, Sarah R.CA, Torrance, United States (författare)
  • van Riel, Piet Leonardus Cornelis MariaIQ Healthcare, Radboud University, Gelderland, Nijmegen, Netherlands; Bernhoven Hospital Location Oss, Rheumatology, Oss, Netherlands (författare)
  • Gonzalez-Gay, Miguel A.Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain; IIS-Fundacion Jimenez Diaz, Madrid, Spain (författare)
  • Corrales, AlfonsoHospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain (författare)
  • Rantapää-Dahlqvist, SolbrittUmeå universitet,Reumatologi(Swepub:umu)sora0001 (författare)
  • Sfikakis, Petros P.First Dept. of Propedeutic Medicine, University of Athens, Attica, Athens, Greece (författare)
  • Dessein, PatrickSchool of Physiology, University of the Witwatersrand Johannesburg, Johannesburg, South Africa (författare)
  • Tsang, LindaVrije Universiteit Brussel, Belgium (författare)
  • Hitchon, CarolUniversity of Manitoba, Rheumatology, MB, Winnipeg, Canada (författare)
  • El-Gabalawy, HaniDepartment of Internal Medicine, University of Manitoba, MB, Winnipeg, Canada (författare)
  • Pascual-Ramos, VirginiaImmunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico (författare)
  • Contreras-Yáñez, IrazúDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico (författare)
  • Colunga-Pedraza, Iris J.Hospital Universitario Dr José Eleuterio González, Rheumatology, Nuevo León, Monterrey, Mexico (författare)
  • Galarza-Delgado, Dionicio AngelHospital Universitario Dr Jose Eleuterio Gonzalez, Rheumatology, Nuevo León, Monterrey, Mexico (författare)
  • Azpiri-Lopez, Jose RamonHospital Universitario Dr José Eleuterio González, Nuevo León, Monterrey, Mexico (författare)
  • Semb, Anne GreteRheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway (författare)
  • Misra, Durga PrasannaClinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Uttar Pradesh, Lucknow, India (författare)
  • Hauge, Ellen-MargretheDepartment of Joint and Connective Tissue Diseases, Aarhus Universitetshospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus Universitet, Aarhus, Denmark (författare)
  • Kitas, GeorgeDepartment of Rheumatology, Dudley Group NHS Foundation Trust, West Midlands, Dudley, United Kingdom (författare)
  • Internal Medicine - Rheumatology, CA, Torrance, United States; Harbor-UCLA Medical Center, Rheumatology, CA, Torrance, United StatesCA, Torrance, United States (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:RMD Open: BMJ Publishing Group Ltd10:32056-5933

Internetlänk

Hitta via bibliotek

  • RMD Open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy